scholarly journals Evaluation of Influenza Vaccine Effectiveness Among Young Children Receiving Consecutive Versus Nonconsecutive Vaccination During Influenza A(H3N2)-Predominant Seasons

2020 ◽  
Author(s):  
Suchitra Rao ◽  
Angela Moss ◽  
Molly M Lamb ◽  
Edwin J Asturias
Keyword(s):  
Influenza Vaccine ◽  
Influenza A ◽  
Care Setting ◽  
Case Control ◽  
Vaccine Effectiveness ◽  
Urgent Care ◽  
Control Analysis ◽  
Negative Case ◽  
Case Control Analysis ◽  
Urgent Care Setting

Abstract A test-negative case-control analysis of 1478 children aged 6 months to 8 years of age seeking care at an emergency/urgent care setting with influenza like illness during the 2016-17 and 2018-19 (H3N2 predominant) influenza seasons demonstrated that influenza vaccine effectiveness did not vary significantly by the prior seasons’ vaccination status. Clinical Trials Registration NCT02979626.

Influenza vaccine effectiveness among Hajj pilgrims: a test-negative case-control analysis of data from different Hajj years

2019 ◽  
Vol 18 (10) ◽  
pp. 1103-1114 ◽  
Author(s):  
Mohammad Alfelali ◽  
Osamah Barasheed ◽  
Parvaiz Koul ◽  
Al-Mamoon Badahdah ◽  
Hamid Bokhary ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Case Control ◽  
Vaccine Effectiveness ◽  
Control Analysis ◽  
Negative Case ◽  
Case Control Analysis

scholarly journals 2731. Does Last Season’s Influenza Vaccination Affect Current Season’s Vaccine Effectiveness in Young Children?

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S961-S961
Author(s):  
Suchitra Rao ◽  
Molly Lamb ◽  
Angela Moss ◽  
Edwin J Asturias
Keyword(s):  
Medical Condition ◽  
Vaccine Effectiveness ◽  
Vaccination Status ◽  
Urgent Care ◽  
Control Analysis ◽  
Current Season ◽  
Logistic Regression Models ◽  
Negative Case ◽  
Influenza Illness ◽  
Case Control Analysis

Abstract Background We evaluated influenza VE over two consecutive years vs. the current season against influenza illness during two H3N2-predominant seasons in children receiving care at emergency/urgent care (ED/UC) facilities in metropolitan Colorado. Methods We conducted a test-negative case–control analysis of 1478 children aged 6 months to 8 years enrolled at Children’s Hospital Colorado ED/UC with influenza like illness during the 2016–2017 and 2017–2018 influenza seasons. The primary outcome was PCR-confirmed influenza and vaccination status was confirmed using electronic medical record and parental interviews. Vaccination status was defined as completely vaccinated (all doses of influenza vaccine according to child’s age); partially or not vaccinated children were defined as unvaccinated. Multivariable logistic regression models adjusted for high-risk medical condition, age, race and insurance status were used to calculate odds ratios (OR) and 95% confidence intervals. Vaccine effectiveness was calculated as (1 − OR) × 100. Results Of the 1224 (82.8%) children enrolled in the study with known vaccination status for both seasons, 361 (29%) tested positive for influenza. Overall, VE against influenza was 49% (95% CI, 33–61%) after adjusting for other covariates in the model. VE did not differ significantly between those vaccinated in both seasons and those vaccinated in only the current season (VE 69%, 95% CI 41–115) (Table 1). Conclusion Our estimates of influenza VE for two predominantly H3N2-influenza seasons in Colorado are comparable to the CDC -VE for children 6 months to 8 years. VE against ED or UC-attended influenza illness in children did not vary significantly by prior seasons’ vaccination status. Disclosures All authors: No reported disclosures.

scholarly journals Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0249005
Author(s):  
Masayoshi Shinjoh ◽  
Norio Sugaya ◽  
Yoshio Yamaguchi ◽  
Ichiro Ookawara ◽  
Yuji Nakata ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Influenza Vaccine ◽  
Diagnostic Tests ◽  
Influenza A ◽  
Control Design ◽  
Case Control ◽  
Vaccine Effectiveness ◽  
Test Results ◽  
Negative Case ◽  
Influenza A H1n1

During influenza epidemics, Japanese clinicians routinely conduct rapid influenza diagnostic tests (RIDTs) in patients with influenza-like illness, and patients with positive test results are treated with anti-influenza drugs within 48 h after the onset of illness. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children (6 months–15 years old, N = 4243), using a test-negative case-control design based on the results of RIDTs in the 2018/19 season. The VE against influenza A(H1N1)pdm and A(H3N2) was analyzed separately using an RIDT kit specifically for detecting A(H1N1)pdm09. The adjusted VE against combined influenza A (H1N1pdm and H3N2) and against A(H1N1)pdm09 was 39% (95% confidence interval [CI], 30%–46%) and 74% (95% CI, 39%–89%), respectively. By contrast, the VE against non-A(H1N1)pdm09 influenza A (presumed to be H3N2) was very low at 7%. The adjusted VE for preventing hospitalization was 56% (95% CI, 16%–77%) against influenza A. The VE against A(H1N1)pdm09 was consistently high in our studies. By contrast, the VE against A(H3N2) was low not only in adults but also in children in the 2018/19 season.

scholarly journals Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 – a rapid epidemiological and virological assessment

2016 ◽  
Vol 21 (14) ◽  
Author(s):  
Hanne Dorthe Emborg ◽  
Tyra Grove Krause ◽  
Lene Nielsen ◽  
Marianne Kragh Thomsen ◽  
Claus Bohn Christiansen ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Influenza A ◽  
Control Design ◽  
Case Control ◽  
Vaccine Effectiveness ◽  
Influenza B ◽  
Trivalent Influenza Vaccine ◽  
Negative Case ◽  
Influenza A H1n1 ◽  
Genetic Subgroup

In Denmark, both influenza A(H1N1)pdm09 and influenza B co-circulated in the 2015/16 season. We estimated the vaccine effectiveness (VE) of the trivalent influenza vaccine in patients 65 years and older using the test-negative case–control design. The adjusted VE against influenza A(H1N1)pdm09 was 35.0% (95% confidence interval (CI): 11.1–52.4) and against influenza B 4.1% (95% CI: −22.0 to 24.7). The majority of influenza A(H1N1)pdm09 circulating in 2015/16 belonged to the new genetic subgroup subclade 6B.1.

scholarly journals Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

2012 ◽  
Vol 141 (3) ◽  
pp. 620-630 ◽  
Author(s):  
R. G. PEBODY ◽  
N. ANDREWS ◽  
D. M. FLEMING ◽  
J. McMENAMIN ◽  
S. COTTRELL ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Vaccine Effectiveness ◽  
Influenza B ◽  
The United Kingdom ◽  
Previous Season ◽  
Negative Case ◽  
Influenza A H1n1 ◽  
Control Study

SUMMARYAn analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-specific adjusted VE was 87% (95% CI 45–97) in <5-year-olds and 84% (95% CI 27–97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI −6 to 51) overall and 72% (95% CI 15–91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42–68) and in 5- to 14-year-olds 75% (95% CI 32–91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

scholarly journals Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe

2017 ◽  
Vol 22 (7) ◽  
Author(s):  
Esther Kissling ◽  
Marc Rondy ◽  
Keyword(s):  
Primary Care ◽  
Influenza Vaccine ◽  
Influenza Vaccination ◽  
Influenza A ◽  
Case Control ◽  
Vaccine Effectiveness ◽  
Hospital Level ◽  
Case Control Studies ◽  
Care Level ◽  
Primary Care Level

We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0–14, 15–64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65–79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).

scholarly journals Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan

2016 ◽  
Vol 21 (42) ◽  
Author(s):  
Norio Sugaya ◽  
Masayoshi Shinjoh ◽  
Chiharu Kawakami ◽  
Yoshio Yamaguchi ◽  
Makoto Yoshida ◽  
...  
Keyword(s):  
New York ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Influenza Season ◽  
Influenza Virus Infection ◽  
Case Control ◽  
H3n2 Virus ◽  
Influenza B ◽  
Influenza A Viruses ◽  
Negative Case

The 2014/15 influenza season in Japan was characterised by predominant influenza A(H3N2) activity; 99% of influenza A viruses detected were A(H3N2). Subclade 3C.2a viruses were the major epidemic A(H3N2) viruses, and were genetically distinct from A/New York/39/2012(H3N2) of 2014/15 vaccine strain in Japan, which was classified as clade 3C.1. We assessed vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children aged 6 months to 15 years by test-negative case–control design based on influenza rapid diagnostic test. Between November 2014 and March 2015, a total of 3,752 children were enrolled: 1,633 tested positive for influenza A and 42 for influenza B, and 2,077 tested negative. Adjusted VE was 38% (95% confidence intervals (CI): 28 to 46) against influenza virus infection overall, 37% (95% CI: 27 to 45) against influenza A, and 47% (95% CI: -2 to 73) against influenza B. However, IIV was not statistically significantly effective against influenza A in infants aged 6 to 11 months or adolescents aged 13 to 15 years. VE in preventing hospitalisation for influenza A infection was 55% (95% CI: 42 to 64). Trivalent IIV that included A/New York/39/2012(H3N2) was effective against drifted influenza A(H3N2) virus, although vaccine mismatch resulted in low VE.

Sign in / Sign up

Export Citation Format

Share Document